Foamable formulation
View Patent ↗The present invention provides DMSO-containing foamable formulations, methods for preparation, and methods of treatment. The formulations can provide good permeability and bioavailability at the target site. Preferably, the formulations are useful for treating osteoarthritis. In one embodiment, the invention provides a foamable formulation for topical use, said formulation comprising DMSO, polyalkylene glycol alkyl ether, an active agent, a monohydric lower alcohol, a diol, and water. Preferably, the active agent is a non-steroidal anti-inflammatory drug, such as diclofenac sodium or ibuprofen.
1. A foamable formulation, said formulation comprising:
(i) dimethyl sulfoxide (DMSO), wherein DMSO is present in an amount ranging from 12-80% w/w;
(ii) a pharmaceutical agent, wherein the pharmaceutical agent is present at up to 10% w/w;
(iii) a polyalkylene glycol alkyl ether, wherein the polyalkylene glycol alkyl ether is present at up to about 10% w/w; and
(iv) a monohydric alcohol, wherein the monohydric alcohol is present at up to about 50% w/w; wherein the foamable formulation is foamable by manual aeration.
2. The foamable formulation of claim 1 , said formulation further comprising propylene glycol and water,
wherein DMSO is present at 20-60% w/w;
wherein the monohydric alcohol is present at 1-50% w/w; and
wherein the propylene glycol is present at 1-15% w/w.
3. The foamable formulation of claim 1 , wherein the formulation is propellant-free.
4. The foamable formulation of claim 1 , wherein said formulation further comprises a propellant to improve metered dosing of the pharmaceutical agent.
5. The foamable formulation of claim 1 , wherein said formulation comprises from 15%-80% w/w DMSO.
6. The foamable formulation of claim 1 , wherein said pharmaceutical agent is a non-steroidal anti-inflammatory drug.
7. The foamable formulation of claim 6 , wherein said non-steroidal anti-inflammatory drug is ibuprofen or a diclofenac salt.
8. The foamable formulation of claim 7 , wherein said non-steroidal anti-inflammatory drug is ibuprofen;
wherein the ibuprofen is present at a concentration of 3-8% w/w, and percentages between; DMSO is present at a concentration of 14-30% w/w; and the polyalkylene glycol alkyl ether is present at up to 3% w/w;
wherein the formulation further comprises (v) a diol and (vi) water;
wherein the diol is present at a concentration of 5-9% w/w; the monohydric lower alcohol is present at a concentration of up to 17% w/w; and the water is present at a concentration of q.s.
9. The foamable formulation of claim 7 , wherein said diclofenac salt is diclofenac sodium.
10. The foamable formulation of claim 9 , wherein diclofenac sodium is present at 1-10% w/w, DMSO is present at 20-60% w/w,
wherein the formulation further comprises (v) propylene glycol and (vi) water; and
wherein the monohydric alcohol is present at 1-50% w/w, propylene glycol is present at 1-15% w/w, and the water is present at a concentration of q.s.
11. The foamable formulation of claim 1 , wherein the polyalkylene glycol alkyl ether is present at up to 5% w/w.
12. The foamable formulation of claim 11 , further comprising 1-15% w/w glycerol.
13. The foamable formulation of claim 11 , wherein said polyalkylene glycol alkyl ether is a polyethylene glycol alkyl ether.
14. The foamable formulation of claim 13 , wherein said formulation further comprises a steroid.
15. The foamable formulation of claim 14 , wherein said steroid is cholesterol; and wherein said formulation comprises at most 0.5% w/w of said steroid.
16. The foamable formulation of claim 15 , wherein said formulation further comprises a surfactant.
17. The foamable formulation of claim 16 , wherein said surfactant is a salt of an aryl sulfonate, alkyl sulfonate, aryl sulfate, or alkyl sulfate.
18. The foamable formulation of claim 17 , wherein said salt is sodium dodecyl benzene sulfonate, sodium laureth sulfate, or sodium lauryl sulfate.
19. The foamable formulation of claim 14 , wherein the formulation further comprises sodium carbonate.
20. A foam comprising the foamable formulation of claim 1 .
21. The foam of claim 20 , further comprising air.
22. The foam of claim 20 , wherein the foam is a quick-breaking foam.
23. A method for treating a subject suffering from pain, said method comprising the topical administration to an afflicted area of said subject a therapeutically effective amount of foamable formulation of claim 1 , wherein said foamable formulation comprises a pharmaceutical agent for the treatment of pain.
24. The method of claim 23 , wherein said pain is associated with osteoarthritis.
25. The method of claim 24 , wherein said topical administration provides a reduction of pain over 12 weeks.
26. The method of claim 24 , wherein said formulation is applied one, two, three, or four times daily.
27. The foamable formulation of claim 1 , wherein said formulation comprises 12-48% w/w DMSO.
28. The foamable formulation of claim 27 , wherein said formulation comprises 14-30% w/w DMSO.
29. The foamable formulation of claim 1 , wherein said polyalkylene glycol alkyl ether is present at up to 2% w/w.
30. The foamable formulation of claim 5 , wherein said formulation comprises 25%-80% w/w DMSO.
31. A method for manually foaming the foamable formulation of claim 1 , the method comprising the steps of:
(i) providing a dispenser comprising a reservoir operably linked in fluid communication with a release assembly;
(ii) filling the reservoir with the foamable formulation; and
(iii) actuating the release assembly to manually aerate the foamable formulation, thereby releasing a foam from the release assembly.